Tests eye drops of insulin in people with glaucoma
Checks whether insulin eye drops are safe in adults with optic nerve disease.
Plain-language title generated from the registry record
Registry title: Topical Insulin for Glaucoma
Key facts
- Where
- Palo Alto, United StatesSee the site
- Phase
- Phase 1
Where in United States
- Byers Eye Institute at Stanford UniversityPalo Alto, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stanford University
- Trial code
- NCT05206877
- Record updated
- 20 October 2026
- Original description
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).Read full original descriptionShow less
Topical Insulin for Glaucoma and Optic Neuropathies
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).
Inclusion: Capable to provide informed consent; Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen; Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched.
Exclusion: Diagnosis of glucose intolerance, type 1 or 2 diabetes mellitus; Pregnant or breastfeeding woman; Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.); Inability to perform reliable visual field; Unable to provide informed consent; Unable to complete the tests and follow-ups required by the study.